Peptide Association

Insights

NewsBlog
Start free intake

DisclosurePeptide Association LLC is a for-profit company. We receive compensation from the clinical providers listed on this site. We are not an accrediting body, a licensing board, or a government-affiliated organization. See exactly how we make money.

All peptides

Cardiovascular · FDA Approved

Eptifibatide (Integrilin)

FDA-approved

How to ask your doctor
Written by Peptide Association Editorial TeamLast reviewed Editorial policy

01 · Overview

A synthetic cyclic heptapeptide modeled on barbourin, a disintegrin from the venom of the southeastern pygmy rattlesnake (Sistrurus miliarius barbouri) that uses a Lys-Gly-Asp (KGD) sequence instead of the usual RGD motif, giving it specificity for platelet glycoprotein IIb/IIIa (PMID 2033037) (PMID 12846593). Eptifibatide is a competitive glycoprotein IIb/IIIa antagonist that prevents fibrinogen binding and cross-linking of activated platelets, blocking the final common pathway of platelet aggregation (PMID 12846593).

The Integrilin brand has been discontinued in the US, but generic eptifibatide remains available.

02 · Research summary & key findings

FDA-approved for acute coronary syndrome and percutaneous coronary intervention. In the PURSUIT trial of patients with acute coronary syndromes without persistent ST elevation, eptifibatide produced a 1.5% absolute reduction in death or nonfatal MI at 30 days (14.2% vs. 15.7%), with more bleeding but no increase in hemorrhagic stroke (PMID 9705684). In the ESPRIT trial of coronary stenting, the 48-hour composite of death, MI, urgent target vessel revascularization or bailout therapy fell from 10.5% to 6.6%, and the trial was stopped early for efficacy (PMID 11145489). Major bleeding was uncommon but more frequent with eptifibatide (PMID 11145489).

03 · Regulatory status

Eptifibatide (Integrilin) has received FDA approval and is available for clinical use under appropriate medical supervision. Consult a qualified healthcare provider for prescribing information.

Eptifibatide (Integrilin) is an FDA-approved medicine prescribed for the conditions on its label. It is not part of our intake, so we do not propose protocols for it. If you think it may be relevant to you, talk to your own doctor. How to ask your doctor.

04 · Administration routes

  • Intravenous

References

  1. [1]Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial Lancet, 2000. PMID 11145489
  2. [2]Platelet glycoprotein IIb/IIIa inhibitors in percutaneous coronary intervention: focus on the pharmacokinetic-pharmacodynamic relationships of eptifibatide Clin Pharmacokinet, 2003. PMID 12846593
  3. [3]Barbourin. A GPIIb-IIIa-specific integrin antagonist from the venom of Sistrurus m. barbouri J Biol Chem, 1991. PMID 2033037
  4. [4]Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes N Engl J Med, 1998. PMID 9705684

Primary literature

Related peptides in Cardiovascular

Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol. See our editorial policy for how this content is produced and reviewed. Clinicians: join the network.